Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.
Checked against the public recordLast updated Jun 14, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Augusta University
- Interventions being studied
- Drug: Cabozantinib; Drug: Pemetrexed
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Locally advanced NSCLC, urothelial cancer or malignant mesothelioma. * 18 years or older. * At least one prior chemotherapy before entering in this trial. * Not pregnant or breastfeeding. Exclusion Criteria: * Prior treatment with cabozantinib. * Currently receiving cancer treatment (last dose 2 weeks prior to enrollment in study). * History of bleeding disorder/bleeding history within 12 weeks before first study treatment dose.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Augusta University Georgia Cancer CenterAugusta, Georgia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 14, 2022. Always confirm current availability with the study team.